Pharmacological Mechanisms, Clinical Efficacy, and Cardiovascular Safety Profile of Oral Erectile Dysfunction Drugs
Oral medications for Erectile Dysfunction ($\text{ED}$), primarily belonging to the class of phosphodiesterase type 5 ($\text{PDE5}$) inhibitors, represent the first-line pharmacological treatment for the majority of men experiencing this common sexual health concern, offering a non-invasive, effective option for improving the physiological capacity for achieving and maintaining an erection sufficient for sexual activity.
These agents act by inhibiting the $\text{PDE5}$ enzyme, which normally degrades cyclic guanosine monophosphate ($\text{cGMP}$) in the penile smooth muscle cells, thereby potentiating the effects of naturally released nitric oxide ($\text{NO}$) and enhancing the necessary vascular relaxation and blood flow required for the erectile process.
The mechanism begins with sexual stimulation, which triggers the release of $\text{NO}$ from nerve endings and endothelial cells. $\text{NO}$ activates guanylate cyclase, increasing the concentration of $\text{cGMP}$, which mediates the relaxation of smooth muscle in the penile corpus cavernosum and its associated arteries, allowing blood to rapidly flow in and become trapped…
